NCT04535700View on ClinicalTrials.gov

Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 18, 2020

Primary Completion Date

November 19, 2021

Study Completion Date

January 10, 2022

Conditions
Type 2 Diabetes
Interventions
DRUG

Pioglitazone 30 mg

Patients receive 30 mg/day of pioglitazone for the entire period they remain in hospital

OTHER

standard of care

Patients receive the standard of care, according to the hospital protocol for patients with type 2 diabetes mellitus hospitalized.

Trial Locations (1)

28034

Hospital Ramón y Cajal, Madrid

All Listed Sponsors
lead

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

OTHER

NCT04535700 - Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19 | Biotech Hunter | Biotech Hunter